Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 14/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4232969 | 1.00 | P2RY12 (0.47) | P2RY12MAPTGRM5JAK1JAK3 | |
| SCHEMBL4226204 | 0.85 | P2RY12 (0.54) | P2RY12 | |
| SCHEMBL4221919 | 0.84 | P2RY12 (0.51) | P2RY12MAPT | |
| SCHEMBL4221758 | 0.83 | MAPT (0.46) | P2RY12MAPTJAK1JAK3 | |
| SCHEMBL5170561 | 0.83 | MAPT (0.46) | P2RY12MAPTJAK1JAK3 | |
| SCHEMBL4520763 | 0.83 | MAPT (0.46) | P2RY12MAPTJAK1JAK3 | |
| SCHEMBL5172104 | 0.80 | P2RY12 (0.44) | P2RY12GRM5 | |
| SCHEMBL4218823 | 0.79 | P2RY12 (0.45) | P2RY12MAPTGRM5JAK1JAK3 | |
| SCHEMBL4217900 | 0.79 | P2RY12 (0.55) | P2RY12 | |
| SCHEMBL4233931 | 0.79 | P2RY12 (0.55) | P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | P2RY12 4728/4885MAPT 3433/4885GRM5 855/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | P2RY12 4581/4885MAPT 3316/4885GRM5 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.